This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEG5M15S_L.jpg
The drugmaker said it has also secured the right to acquire remainder of Pionyr for a $315 million option exercise fee.
Gilead to buy 49.9% stake in cancer drug developer Pionyr for $275 million
5 years ago
No Comments
Related Posts
U.S. labor board denies Amazon's request to halt Alabama union election
February 5, 2021
China Evergrande Shares on the Rise as Talks to Sell Assets Begin
August 11, 2021
Goldman Sachs says it's climbing toward Fed's capital demands
June 29, 2020
Car parts group Valeo drops 2020 targets, gets 1 billion euros of new credit lines
April 14, 2020
Barclays kickstarts suspended share buy-back programme
May 24, 2022
Germany stocks lower at close of trade; DAX down 0.61%
December 3, 2021
About The Author
